Resmetirom is a Small Molecule owned by Madrigal Pharmaceuticals, and is involved in 16 clinical trials, of which 11 were completed, and 5 are ongoing.
Resmetirom (MGL-3196, VIA-3196, THR-Beta agonist 3196) act as liver-directed THR-beta agonist. Thyroid hormone receptors (TRs) work as transcription factors and it exists in two subtypes: TRalpha and TRbeta. TRbeta mediates cholesterol and TSH lowering effects of thyroid hormones. TR beta activation modestly increases metabolic rate. The mechanism by which THR beta lowers cholesterol is believed to primarily be mediated by increased cholesterol excretion out of the body through the bile. The compound also reduces triglycerides in the liver by increasing fat metabolism.
The revenue for Resmetirom is expected to reach a total of $3.3bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Resmetirom NPV Report.
Resmetirom (MGL-3196, VIA-3196, THR-Beta agonist 3196) is under development for the treatment of non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis. The therapeutic candidate is formulated as tablet and orally administered. The therapeutic candidate acts by targeting beta-selective thyroid hormone receptor.
It was also under development for the treatment of heterozygous and homozygous familial hypercholesterolemia (HeFH, HoFH).
Madrigal Pharmaceuticals Overview
Madrigal Pharmaceuticals (Madrigal), formerly Synta Pharmaceuticals Corp, is a biopharmaceutical company with focus on the development and commercialization of novel drugs for the treatment of liver, cardiovascular and metabolic diseases. Its lead product candidate, resmetirom (MGL-3196), is a proprietary, liver-directed, selective thyroid hormone receptor beta (THR-beta) agonist that can potentially help treat several diseases with high unmet medical need. The company is developing resmetirom for non-alcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD), associated dyslipidemias and familial hypercholesterolemia (FH). The company is also developing MGL-3745 (THR-beta agonist), a preclinical compound that has thyroid receptor selectivity similar to that of MGL-3196. Madrigal is headquartered in West Conshohocken, Pennsylvania, the US.
The operating loss of the company was US$242.5 million in FY2021, compared to an operating loss of US$206.7 million in FY2020. The net loss of the company was US$241.9 million in FY2021, compared to a net loss of US$202.2 million in FY2020.
Quick View – Resmetirom
|Highest Development Stage|